Home

ALNYLAM PHARMACEUTICALS, INC.

CIK 1178670 · last filed 2016-02-24

ALNYLAM PHARMACEUTICALS, INC. is a corporate insider who has filed 20 SEC Form 4 insider transactions across 1 company since 2012. The most recent filing shows the insider sold $7.2M of RGLS on Feb 24, 2016. Across all open-market trades the lifetime net is −$11.3M, making them a net seller over the disclosed history. The firm reports its address in Cambridge, MA. 90 SEC filings were submitted jointly with JOHN MARAGANORE.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

20

Lifetime Open-Market Net

-$11.28M

Filer Profile

Reported Address
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE, MA 02142
Phone
(617) 551-8200
Formerly Known As
ALNYLAM PHARMACEUTICALS INC (2002–2004)
Related Filers
JOHN MARAGANORE — 90 joint filings, latest 2021-12-23
Akshay Vaishnaw — 71 joint filings, latest 2023-12-11
Yvonne Greenstreet — 63 joint filings, latest 2026-03-06
Barry E Greene — 62 joint filings, latest 2020-09-11
PHILLIP A SHARP — 51 joint filings, latest 2025-05-30
Pushkal Garg — 40 joint filings, latest 2026-03-06
LAURIE KEATING — 39 joint filings, latest 2021-08-09
PAUL SCHIMMEL — 37 joint filings, latest 2019-07-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Regulus Therapeutics Inc. (RGLS) Delisted 10%+ Owner 40,806 $8.16 $333.0K -$11.28M 20 2016-02-24

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-02-24 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −1,000,000 -$7.18M EDGAR
2014-10-28 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −113,084 -$1.59M EDGAR
2014-10-24 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −113,084 -$1.59M EDGAR
2014-10-17 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −12,100 -$81.5K EDGAR
2014-10-10 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −10,050 -$65.9K EDGAR
2014-10-03 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −10,300 -$69.4K EDGAR
2014-09-26 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −8,750 -$62.4K EDGAR
2014-09-19 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −7,700 -$56.3K EDGAR
2014-09-12 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −8,900 -$69.9K EDGAR
2014-09-05 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −10,050 -$71.1K EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.